EANS-News: SYGNIS Pharma AG / SYGNIS´ reduction of share capital in a 3:1 ratio was entered in the commercial register

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Heidelberg (euro adhoc) - SYGNIS´ reduction of share capital in a 3:1 ratio was
entered in the commercial
register

Heidelberg, 15 December 2010 - SYGNIS Pharma AG (Frankfurt: LIO; ISIN
DE0005043509; Prime Standard) today announced the registration of the capital
reduction in the commercial register on the basis of the resolution of the
Annual General Meeting held on 30 November 2010. Hereby the share capital is
reduced from EUR 41,258,643 to EUR 13,752,881, allocated to 13,752,881
shares outstanding.

At the same time the implementation of the capital reduction on the stock
exchange and the consolidation of the shares in a 3:1 ratio were initiated. It
is expected that the consolidation of the shares will be completed by the end
of December 2010. Due to this process the trading of the SYGNIS shares on the
stock exchange will be temporarily suspended.

The purpose of this capital reduction is primarily to improve the Company´s
abilities to interact on the capital markets and to open up financing
alternatives, since the Company´s share price has been below the nominal value
of EUR 1 for a long period. It is anticipated that this move will better support
the development of the shares.

About SYGNIS Pharma
SYGNIS Pharma AG, headquartered in Heidelberg, is a specialty pharmaceutical
company listed on the Prime Standard of the German stock exchange. The Company
is focused on the research and development of innovative therapies for the
treatment of disorders of the Central Nervous System. SYGNIS´ core projects are
currently Acute Stroke for which SYGNIS´ lead clinical programme is AX200 as
well as the preclinical KIBRA-project for the treatment of different forms of
dementia. All these disorders are characterized by the fact that, as the
disease progresses, nerve cells are damaged and die. Although there is great
medical demand, there are currently no or only inadequate treatment options
available. SYGNIS´ strategy for growth includes the development of new products
from its own research and through in-licensing and acquisitions.

For further information please contact:
SYGNIS Pharma AG:
Dr. Franz-Werner Haas
Vice President Operations
+49 (0) 6221 454 812
franz-werner.haas@sygnis.de

Media-Contact:
Julia Phillips
Financial Dynamics
Tel.: +44 (0) 20 7269 7187

### Disclaimer
Some statements included in this press release, relating neither to proven
financial results nor other historical data, should be viewed as forward-
looking, i.e. not definite. Such statements are mainly predictions of future
results, trends, plans or goals. These statements should not be considered to
be total guarantees since given their very nature they are subject to known and
unknown risks and imponderability and can be affected by other factors as a
consequence of which the actual results, plans and goals of SYGNIS Pharma AG
may deviate greatly from the established conclusions or implied predictions
contained in such statements. SYGNIS does not undertake to publicly update or
revise these statements in the light of new information or future results or
for any other reason. ###

Further inquiry note:
Dr. Franz-Werner Haas
Vice President Operations
+49 (0) 6221 454 812
franz-werner.haas@sygnis.de
end of announcement euro adhoc
--------------------------------------------------------------------------------

company: SYGNIS Pharma AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 (0)6221 454-6
FAX: +49 (0)6221 454-777
mail: contact@sygnis.de
WWW: http://www.sygnis.de
sector: Biotechnology
ISIN: DE0005043509
indexes: CDAX, Prime All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
Hamburg, Stuttgart, Düsseldorf, Hannover, München
language: English

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | CNE

print